Autoimmune Brain Panel™ (formerly Cunningham Panel™)

Performed by: Moleculera Labs

The Autoimmune Brain Panel™—commonly known as the Cunningham Panel™—is a specialized neuro-immune test designed to measure autoantibodies and cell-signaling activity associated with PANS, PANDAS, Sydenham chorea, and other neuropsychiatric conditions linked to immune dysregulation.

This panel evaluates whether the immune system is producing antibodies that may mistakenly target neuronal tissue, particularly structures involved in movement, behavior, mood, memory, and executive function. These autoantibodies can influence dopamine signaling and activate intracellular pathways, potentially contributing to sudden-onset symptoms such as OCD, anxiety, tics, mood changes, or cognitive decline.

The panel includes five biomarkers:

Anti-Dopamine Receptor D1 (DRD1)
Anti-Dopamine Receptor D2L (DRD2L)
Anti-Lysoganglioside GM1
Anti-Tubulin
CaM Kinase II (CaMKII) activation

Together, these markers help identify immune-mediated disruption of neuronal signaling, a pattern observed in autoimmune neuropsychiatric disorders. While this panel does not diagnose PANS/PANDAS on its own, it offers meaningful supportive evidence when interpreted with clinical symptoms, history of infection, and other immune markers such as ASO and anti-DNase B.

Because the reference ranges are derived largely from pediatric controls, interpretation must be done in the context of age, symptoms, and clinical assessment.

This panel is performed exclusively by Moleculera Labs, a CLIA-certified laboratory specializing in neuro-immune diagnostics.

Autoimmune Brain Panel™ (formerly Cunningham Panel™)

Performed by: Moleculera Labs

Biomarkers included in this panel:

Anti-Dopamine Receptor D1 (DRD1), Titer

Anti-Dopamine Receptor D2L (DRD2L), Titer

Anti-Lysoganglioside GM1, Titer

Anti-Tubulin, Titer

CaM Kinase II (CaMKII), % of Baseline

All Categories